Menu
Menu
Therma Bright Inc. is a publicly traded company (TSVX:THRM) focused on servicing the $21 billion cosmeceutical industry. Therma Bright Inc. holds patents pending and the trademarks for Therozap™ and the trademark InterceptCS™ along with with regulatory approvals for its breakthrough thermal therapy technology. The Company’s technology uses heat and light energy to deliver effective, topical, pain free skin care.
Therma Bright Inc. has spent a significant investment in intellectual property and research and development for its InterceptCS™- cold sore device, the Therozap™ insect device, and will soon invest in a novel pain relief device. Therma’s current product lines address cold sore treatment and prevention, and the treatment of pain, itch and inflammation related to mosquito, bee, spider, mite, and jellyfish bites or stings. Therma Bright is in the research and development stage to develop a novel device for relief of pain associated with back, knee or other joint pain. Therma Bright is focused on building recurring revenue streams from its products and to incorporate intelligent technology such as AI or IoT.
The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.
The Company is currently pursuing the redesign of Therma’s existing platforms to commercialize on new technologies.
Per John Cumbers Senior Contributor for Forbes, “COVID-19 has brought the diagnostics market into the spotlight and exposed a rapidly growing need for better testing capabilities to not only to fight this and future pandemics, but also transform the nature of healthcare delivery.”
According to Grand View Research, the global COVID-19 diagnostics market size is estimated at USD 84.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027. This new COVID-19 market has been driven by global government efforts toward the adoption and implementation of mass serial testing and vaccinations initiatives.
Current efforts are moving toward vaccinations and at-home testing that are integrating technology and software for tracking and reporting on vaccinations and test results and validation. This is expected to increase patient convenience in regard to time-consuming laboratory-based testing. The demand for COVID-19 diagnostic products is set to propel further with the increasing number of coronavirus-infected patients, particularly post the ease of lockdown across the globe.
New testing programs and protocols are set to pave way for the travel industry, sports and entertainment, hospitality and educations, all have led to an dramatic surge in COVID-19 testing in 2021, and expected to continue to propel the Point-of-Care (pop) and at-home testing market penetration. Complex and pure reagents, such as probes, enzymes, and primers, will become crucial for conducting both antigen and antibody tests.
AcuVid™ COVID-19 RAPID ANTIGENT TEST: Therma Bright is positioned well for this COVID-19 diagnostic marketplace, with its high performing test results from its initial frozen saliva samples to testing in Brazil at the Federal University of Minas Gerais (UFMG), and the successful testing of live human saliva for the original COVID19 virus (Wuhan SARS-CoV-2)as well as the detection of the growing list of variants including Brazilian P.1 and P.2 and the UK B.1.1.7 variants.
Furthermore, The company announced white labeling its latest rapid COVID-19 antibody blood test, to be branded under AcuVid™ COVID-19 RAPID ANTIBODY TEST, which detects both the IgG and IgM antibodies against SARS-CoV-2 in a15-minute serology/blood test. This pinprick antibody blood test uses a small amount of blood and has a 96.6% sensitivity for detecting antibodies of SARS-CoV-2 in those individuals currently infected with the virus or who have previously been infected, but went undiagnosed or were unaware of their infection. It will also aid in determining antibodies generated by those who have received a COVID-19 vaccine.
In April 2021, the Company recently signed a memorandum of understanding with a high-tech firm to create a smart-enable test solution for tracking and reporting initially for PoCm then for At-Home use and validations/verification. Therma Bright’s goal is to create a “Brighter Experience” which includes a complete end-to-end solution to ensure product tracking, quality control and test validation data are all cryptographically captured and secured to protect individual privacy for every test taken.
Per Grand View Research, the global pain management devices marketplace was valued at $5.54 Billion USD in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2020 to 2027. The increasing cases of chronic diseases is one of the key factors expected to contribute to the growth of this pain management device marketplace during the period. The growing prevalence of lifestyle disorders, such as obesity and diabetes, has increased the demand for muscle and nerve stimulators. In addition, the rise in cancer cases are expected to further increase pain management device demand, as will musculoskeletal disorders, like arthritis, osteoarthritis, orthopedic degenerative disorders, and rheumatoid arthritis
ThermaBright is perfectly positions to capture a piece of this large and growing global marketplace for pain management devices with its three uniques solutions for relieving pain caused by muscle and joint aches, cold sores and blood clots.
Benepod: ThermaBright’s leading-edge Benepod device, is a pain management device the provides a hot and cold stimulus to a individuals aches and muscle sore, offering instant relief
Intercept CS: ThermaBright’s innovative patent-pending cold sore prevention device uses light and infrared combined to penetrate deep into the skin killing the virally infected cells that cause cold sores and the pain they cause.
Venowave: unique message device designed to treat and alleviate the symptoms associated with poor circulation, including the prevention go blood pooling and clotting, as well as alleviates painful symptoms from Post Thrombotic Syndrome and other Chronic Venous Insufficiencies.
The skincare market is undergoing rapid growth fueled by an aging population, advances in skincare, and the convergence of pharmaceutical and cosmetics products – “cosmeceuticals”. Like cosmetics, cosmeceuticals are topically applied, but they contain ingredients that influence the biological function of the skin. Dermatological research suggests that the bioactive ingredients used in cosmeceuticals have benefits beyond the traditional cosmetics and thus provide protection, prevention and regeneration that surpass traditional cosmetics.
Today, as the demand increases for effective skin care treatments, consumers continue to educate themselves in the selection of home care products and alternatives to expensive procedures. Products that help people feel better and provide actual skin repair from the comfort of their home are expected to become the focus of the anti-aging skincare industry.
According to Industry Research study, The Consumer Skin Care Devices market revenue was $3.937 Billion USD in 2019, and will reach $4.529 Billion USD in 2025, with a CAGR of 2.36% during 2020-2025. Skin care is a series of practices that support skin integrity, enhance skin appearance and relieve skin condition. They can include nutrition, avoid excessive sun exposure and proper use of emollients. Practices to enhance appearance include the use of cosmetics, botulinum, exfoliation, fillers, laser surface resurfacing, microdermabrasion, skin, and retinol treatment.
Therma occupies a unique market position in this Consumer Skin Care Devices marketplace. Its innovative products tap into a new approach to skin care, combining clinically proven and scientifically endorsed technology with a cost-effective and efficient delivery method to treat a variety of skin conditions while providing a recurring revenue stream for the Company.
Therma Bright plans to test its Therozap™ technology at inhibiting the Zika virus and other mosquito borne diseases in the human body. After consultation with various research laboratories specialized in studying mosquito borne disease, Therma Bright intends to test the TherOZap™ technology against the Zika and Dengue viruses.
According to the World Health Organization: “Dengue effects a much larger percentage of the world population with about half of the world’s population now at risk. Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas. Severe dengue is a leading cause of serious illness and death among children in some Asian and Latin American countries.”
The Dengue, Zika and West Nile viruses are spread by the same mosquito which is known as the Aedes Aegypti mosquito. The Aedes Aegypti mosquito is known as a prolific daytime biter which often makes it harder for people to protect themselves after an infectious bite.
Therma Bright intends to test its TherOZap™ technology and hopes to prove the technology will be effective as a second line of defense after an individual has been bitten.
In addition, Therma Bright Inc. has gained a better understanding about the Zika virus through consultation with research groups and that the Zika and Dengue viruses may be susceptible to die-off with the use of the Company’s TherOZap™ technology. Once testing of the Company’s prototypes has been completed the Company intends to apply for regulatory approved claims and to market a consumer ready product to a large potential marketplace.
ThermaBright is perfectly positions to capture a piece of this large and growing global marketplace for pain management devices with its three uniques solutions for relieving pain caused by muscle and joint aches, cold sores and blood clots.
Benepod: ThermaBright’s leading-edge Benepod device, is a pain management device the provides a hot and cold stimulus to a individuals aches and muscle sore, offering instant relief
Intercept CS: ThermaBright’s innovative patent-pending cold sore prevention device uses light and infrared combined to penetrate deep into the skin killing the virally infected cells that cause cold sores and the pain they cause.
Venowave: unique message device designed to treat and alleviate the symptoms associated with poor circulation, including the prevention go blood pooling and clotting, as well as alleviates painful symptoms from Post Thrombotic Syndrome and other Chronic Venous Insufficiencies.
Copyright © 1997-2023 – Therma Bright – All Rights Reserved
